IAVI Report

Work is underway but obstacles to vaccine procurement and delivery for the next pandemic loom large.

After decades of research, structure-based design efforts are yielding effective vaccines against respiratory syncytial virus. Jason McLellan explains the breakthroughs that paved the way.

More and more people living with HIV are over 50 years old, raising new questions about efforts to slow the aging process in a population of individuals on antiretroviral therapy.

Hundreds of next-generation COVID-19 vaccines are being explored, including many that are delivered mucosally to try to prevent infection or block transmission.

After more than 50 years, Anthony Fauci leaves behind an unparalleled legacy of championing science, particularly HIV/AIDS treatment, prevention, and cure efforts.

The emergence of the Sudan strain of Ebola virus in Uganda prompted a rush to get vaccine candidates ready. Expectations are it will be needed in the future.

Two vaccines are poised for delivery against this old foe. What will it take for them to change the field?

Chris Beyrer, director of the Duke Global Health Institute and a renowned epidemiologist, discusses the monkeypox outbreak and the U.S. response.

HIV cure researchers are energized by news of another case of remission and the development of new tools that could help researchers evaluate how well other cure strategies are working.

Therapeutic antibodies against SARS-CoV-2 were developed faster than any other intervention, but their use remains limited. What lessons are there for the development of other monoclonal antibody products, including those for HIV?

An interview with Bali Pulendran on how adjuvants might extend the durability of mRNA-based vaccine protection.

Clinical research data is precious. The IAVI DataSpace platform seeks better ways to store, manage, and share this information securely so it can be used to advance medical research.